Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01743651
Other study ID # OS440-3002
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 2012
Est. completion date April 2014

Study information

Verified date May 2014
Source RVL Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity. Eligible subjects will be removed from anti-spasticity medications for at least one week and then begin study drug treatment with daily doses increasing up to the target dose which will then be maintained for at least 12 weeks. A down-titration will then occur over two weeks.


Description:

This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity. Eligible subjects will be removed from anti-spasticity medications for at least one week and then begin study drug treatment with daily doses increasing up to the target dose which will then be maintained for at least 12 weeks. A down-titration will then occur over two weeks with the final study visit occurring at 19 weeks from start of achieving the target dose or 22 weeks from the Study Visit 1.


Recruitment information / eligibility

Status Completed
Enrollment 353
Est. completion date April 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients (male or female) 18 to 65 years of age, inclusive, at the time of dosing - Have an established diagnosis (per McDonald Criteria) of Multiple Sclerosis (either relapsing remitting or secondary progressive course), that manifests spasticity for at least 6 months - Spasticity due to MS as shown by a TNmAS score equal or greater than six (=6) in the most affected limb. - EDSS equal or greater than 3.0 - If receiving disease-modifying medications, these must have been at a stable dose for at least three (3) months prior to screening, and the subject must be willing to maintain this treatment for the duration of the study - Stable regimen for at least thirty (30) days prior to study entry for all medications and non-pharmacological therapies that are intended to alleviate spasticity - Absence of infections, peripheral vascular disease, painful contractures, advanced arthritis, or other conditions that hinder evaluation of joint movement - Have a creatinine clearance, as calculated by Glomerular Filtration Rate using the Modification of Diet in Renal Disease (MDRD) Study equation, greater than 60mL/min. - Use of a medically highly effective of birth control during the study and for ninety (90) days thereafter for women of child-bearing potential (including female subjects and female partners of non-sterile male subjects) - Willing to allow his or her general practitioner and consultant, if appropriate, to be notified of participation in the study Exclusion Criteria: - Any concomitant disease or disorder that has symptoms of spasticity or that may influence the subject's level of spasticity - Inability to rate their level of spasticity or distinguish it from other MS symptoms - Acute MS exacerbation requiring treatment within twelve (12) weeks of screening - Use of intravenous methylprednisolone within the twelve (12) weeks before visit 1 - Concomitant use of medications that would potentially interfere with the actions of the study medication or outcome variables - Use of botulinum toxin A or B within six (6) months of visit 1 - History of allergy to baclofen or any inactive component of test or reference formulation - Pregnancy, lactation or planned pregnancy during the course of the study and for three (3) months thereafter. - History of unstable psychiatric disease, or current signs and symptoms of significant medical disorders such as severe, progressive, or uncontrolled pulmonary, cardiac, gastrointestinal, hepatic, renal, genitourinary, hematological, endocrine, immunologic, or neurological disease - History of seizures - Current significant cognitive deficit, severe or untreated anxiety, severe or untreated depression - Subjects with abnormal micturition that requires indwelling or intermittent catheterization or with lower urinary tract symptoms (LUTS) that result in a score greater than twenty-six (>26) in the Baseline USPĀ© questionnaire - Current malignancy or history of malignancy that has not been in remission for more than five (5) years, except effectively treated basal cell skin carcinoma - Any other significant disease, disorder or significant laboratory finding which, in the opinion of the investigator, put the subject at risk because of participation, influence the result of the study, or affect the subject's ability to participate - Planned elective surgery or other procedures requiring general anesthesia during the study - Subject who is inappropriate for placebo medication in the judgment of the Investigator - History of substance abuse within the past twelve (12) months - Current chronic use of long acting opioids or round the clock use of short acting opioids for the treatment of pain - Participation in another research study within thirty (30) days of Screening - Patients who are uncooperative or unwilling to sign consent form

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
arbaclofen
40 mg/day as 20 mg arbaclofen ER administered orally 2 times per day
baclofen
80 mg/day as 20 mg baclofen administered orally 4 times per day
Placebo
arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day

Locations

Country Name City State
Russian Federation Osmotica Site-511 Krasnoyarsk
Russian Federation Osmotica Study Site-508 Krasnoyarsk
Russian Federation Osmotica Study Site-510 Krasnoyarsk
Russian Federation Osmotica Study Site-501 Moscow
Russian Federation Osmotica Study Site-502 Moscow
Russian Federation Osmotica Study Site-509 Pyatigorsk Stavropol Krai
Russian Federation Osmotica Study Site-506 Sestroretsk
Russian Federation Osmotica Study Site-507 St Petersburg
Russian Federation Osmotica Study Site-503 St. Petersburg
Russian Federation Osmotica Study Site-505 St. Petersburg
Russian Federation Osmotica Study Site-510 Tonnel'nyy Stavropol Krai
Ukraine Osmotica Study Site 614 Chernigov
Ukraine Osmotica Study Site-602 Dnipropetrovsk
Ukraine Osmotica Study Site-603 Dnipropetrovsk
Ukraine Osmotica Study Site-609 Dnipropetrovsk
Ukraine Osmotica Study Site-611 Donetsk
Ukraine Osmotica Study Site-613 Ivano-Frankivsk
Ukraine Osmotica Site-605 Kharkov
Ukraine Osmotica Study Site-604 Kharkov
Ukraine Osmotica Study Site-610 Kharkov
Ukraine Osmotica Study Site-606 Lviv
Ukraine Osmotica Study Site-608 Odessa
Ukraine Osmotica Study Site-615 Uzhgorod
United States Osmotica Study Site-101 Ann Arbor Michigan
United States Osmotica Study Site-123 Aurora Colorado
United States Osmotica Study Site-124 Baltimore Maryland
United States Osmotica Study Site-110 Bradenton Florida
United States Osmotica Study Site-106 Charlotte North Carolina
United States Osmotica Study Site-131 Cincinnati Ohio
United States Osmotica Study Site-138 Cullman Alabama
United States Osmotica Study Site-108 Fort Wayne Indiana
United States Osmotica Study Site-115 Johnson City New York
United States Osmotica Study Site-116 Lenexa Kansas
United States Osmotica Site-143 Long Beach California
United States Osmotica Study Site-142 Maitland Florida
United States Osmotica Study Site-113 New York New York
United States Osmotica Study Site-125 New York New York
United States Osmotica Study Site-141 New York New York
United States Osmotica Study Site-126 Northbrook Illinois
United States Osmotica Study Site-119 Ormond Beach Florida
United States Osmotica Study Site-127 Pittsburgh Pennsylvania
United States Osmotica Study Site-120 Pompano Beach Florida
United States Osmotica Study Site-133 Salt Lake City Utah
United States Osmotica Study Site-112 San Antonio Texas
United States Osmotica Study Site-129 Seattle Washington
United States Osmotica Study Site-136 Springfield Massachusetts
United States Osmotica SIte-144 Tacoma Washington
United States Osmotica Study Site-109 Tampa Florida

Sponsors (2)

Lead Sponsor Collaborator
RVL Pharmaceuticals, Inc. Osmotica Pharmaceutical US LLC

Countries where clinical trial is conducted

United States,  Russian Federation,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy as determined by Total Numeric Transformed Modified Ashworth scale (TNmAS) in the most affected limb. Change from baseline through end of treatment in the pre-dose, morning TNmAS of the most affected limb. The most affected limb is determined at baseline using the sum of scores for three major motor groups. High scores indicate more severe spasticity. Change in baseline from Visit 1 through Visit 9 (120 days) or end of treatment
Primary Clinical Global Impression of Change (CGIC) through end of treatment The CGIC is a global rating scale that captures the investigator's assessment of the subject's change in overall functional performance since starting the study. Scores range from -3 (significant worsening) to +3 (significant improvement. Visit 9 (120 days) or end of study
Secondary Changes in the Multiple Sclerosis Spasticity Scale (MSSS-88) This MSSS-88 is a self-administered questionnaire for the subject to assess overall functional performance and sense of impairment with respect to the level of spasticity. Baseline through Visit 9 (120 days)
Secondary Changes in the TNmAS for the most affected limb The modified Ashworth Scale is a six (6)-point rating scale that measures abnormality in tone or the resistance to passive movements. Measurements are made in three muscle groups of each limb. The most affect limb is determined at baseline, based on the sum of scores from each limb. Higher scores indicate more severe spasticity. From baseline to visits 4 (22 days), 5 (36 days), 6 (50 days), 7 (71 days), and 9 (120 days)
Secondary Changes in the TNmAS for the sum of all limbs The sums of scores from all limbs are compared to the baseline sum. Higher scores indicate more severe spasticity. Baseline to visits 4 (22 days), 5 (36 days), 6 (50 days), 7 (71 days), and 9 (120 days)
Secondary Changes in Expanded Disability Status Score (EDSS) The EDSS is based on an examination by a neurologist with a scale that ranges from zero (0) to ten (10) in half point (0.5) unit increments. Higher scores represent higher levels of disability. Baseline to Visit 9 (120 Days)
Secondary Changes in the Lower Extremity Manual Muscle Testing (LEMMT) Scale The LEMMT Scale is an evaluation of the function and strength of individual muscles and muscle groups based on effective performance of limb movement in relation to the forces of gravity and manual resistance. Maximum muscular strength is the maximum amount of tension or force that a muscle or muscle group can voluntarily exert in one maximal effort. Scores for each muscle or muscle group range from 0 (no detectable activity) to 5 (normal activity). Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days)
Secondary Changes in Epworth Sleepiness Scale (ESS) The ESS is used to determine the level of daytime sleepiness. The questionnaire asks the subject to rate his or her probability of falling asleep on a scale of increasing probability from 0 to 3 in eight different situations. Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days)
Secondary Changes in the subject-recorded mean daily Drowsiness Numerical Rating Scale (DNRS)score for the day prior to each visit Drowsiness will be reported by the subject using a numerical rating scale with a range of zero (0; no drowsiness) to ten (10; worst possible drowsiness). Scores will be recorded every 3 hours during the day before each designated visit. Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days)
Secondary Changes in the Urinary Symptom Profile (USP) Scale The USP is a Health-Related Quality of Life questionnaire composed of 13 items assessing urinary symptoms in adults with stress, urge, overactive bladder, or urinary obstructive symptoms. Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days)
Secondary Clinical Global Impression of Change (CGIC) The CGIC scores will be recorded at the designated intervals prior to Visit 9 (end of study) Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days)
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis